Einloggen

Thematische Bibliographien / Antibodies / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Antibodies.

Zeitschriftenartikel zum Thema „Antibodies“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 29. Juli 2024

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Antibodies" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Deora, Kanika, und Ruchee Khanna. „Clinical Profile of the Patients with Antiphospholipid Antibodies: Lupus Anticoagulant and Anticardiolipin Antibodies“. Indian Journal of Forensic Medicine and Pathology 12, Nr. 3 (2019): 195–99. http://dx.doi.org/10.21088/ijfmp.0974.3383.12319.6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Chiswell, David J., und John McCaffery. „Phage antibodies: will new ‘coliclonal’ antibodies replace monoclonal antibodies?“ Trends in Biotechnology 10 (1992): 80–84. http://dx.doi.org/10.1016/0167-7799(92)90178-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Linhardt, Robert J., C. W. Abell, R. M. Denney, B. W. Altrock, R. Auerbach, S. D. Bernal, R. E. Canfield et al. „Monoclonal antibodies and immobilized antibodies“. Applied Biochemistry and Biotechnology 15, Nr. 1 (Juni 1987): 53–80. http://dx.doi.org/10.1007/bf02798506.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Favoreel, Herman W., Geert Van Minnebruggen, Gerlinde R. Van de Walle, Jolanta Ficinska und Hans J. Nauwynck. „Herpesvirus interference with virus-specific antibodies: Bridging antibodies, internalizing antibodies, and hiding from antibodies“. Veterinary Microbiology 113, Nr. 3-4 (März 2006): 257–63. http://dx.doi.org/10.1016/j.vetmic.2005.11.003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Clark, A. „Antibodies“. Journal of Clinical Pathology 42, Nr. 5 (01.05.1989): 559. http://dx.doi.org/10.1136/jcp.42.5.559-c.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Bradbury, Andrew, Nileena Velappan, Vittorio Verzillo, Milan Ovecka, Leslie Chasteen, Daniele Sblattero, Roberto Marzari, Jianlong Lou, Robert Siegel und Peter Pavlik. „Antibodies in proteomics I: generating antibodies“. Trends in Biotechnology 21, Nr. 6 (Juni 2003): 275–81. http://dx.doi.org/10.1016/s0167-7799(03)00112-4.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Kounis, Nicholas G., George D. Soufras und George N. Kounis. „Antibodies against antibodies inducing Kounis syndrome“. International Journal of Cardiology 168, Nr. 5 (Oktober 2013): 4804–5. http://dx.doi.org/10.1016/j.ijcard.2013.07.037.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Trier, Nicole, Paul Hansen und Gunnar Houen. „Peptides, Antibodies, Peptide Antibodies and More“. International Journal of Molecular Sciences 20, Nr. 24 (13.12.2019): 6289. http://dx.doi.org/10.3390/ijms20246289.

Der volle Inhalt der Quelle

Annotation:

The applications of peptides and antibodies to multiple targets have emerged as powerful tools in research, diagnostics, vaccine development, and therapeutics. Antibodies are unique since they, in theory, can be directed to any desired target, which illustrates their versatile nature and broad spectrum of use as illustrated by numerous applications of peptide antibodies. In recent years, due to the inherent limitations such as size and physical properties of antibodies, it has been attempted to generate new molecular compounds with equally high specificity and affinity, albeit with relatively low success. Based on this, peptides, antibodies, and peptide antibodies have established their importance and remain crucial reagents in molecular biology.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Matraszek, Veronika Viktoria, Hynek Heřman und Ilona Hromadníková. „The relevance of antiphospholipid antibodies in obstetrics“. Česká gynekologie 89, Nr. 3 (22.06.2024): 237–44. http://dx.doi.org/10.48095/cccg2024237.

Der volle Inhalt der Quelle

Annotation:

Summary: Aim and methodology: To provide a comprehensive review on new findings and current recommendations regarding antiphospholipid antibodies with particular emphasis on clinical impact on gestation. Conclusion: Antiphospholipid antibodies are an important risk factor for the development of a series of pregnancy-related complications. Early diagnosis and appropriate therapy can reduce the incidence of pregnancy loss and pregnancy-related complications. Key words: antiphospholipid antibodies – antiphospholipid syndrome – lupus anticoagulant – anticardiolipin antibodies – anti-ß2-glycoprotein I antibodies

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Shoenfeld, Yehuda. „The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies“. Nature Medicine 10, Nr. 1 (Januar 2004): 17–18. http://dx.doi.org/10.1038/nm0104-17.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Bobrovnik, S. A., M. O. Demchenko und S. V. Komisarenko. „Effect of trifluoroethanol on antibodies binding properties“. Ukrainian Biochemical Journal 95, Nr. 1 (26.04.2023): 20–30. http://dx.doi.org/10.15407/ubj95.01.020.

Der volle Inhalt der Quelle

Annotation:

The studies on the influence of organic co-solvents on the structure and function of antibodies are of key interest, especially in view of antibodies broad use as recognizing elements in different analytical systems. Here we studied the effect of co-solvent 2,2,2-trifluoroethanol (TFE) on the ability of anti-ovalbumin monoclonal antibodies to interact with its specific antigen. Antibody affinity to antigen and the rate constants of antibody binding to immobilized antigen were analyzed. Changes in antibody reactivity with incubation time which depended on TFE concentration and temperature were revealed. When treatment of antibodies with TFE was carried out at 0°C, we observed nonlinear, non-monotonous changes of antibody reactivity with initial fast decrease and substantial increase that may be related to the loss of antigen binding reactivity by some part of antibodies at the start but its restoration when the incubation proceeds. Keywords: 2;2;2-trifluoroethanol, antibody affinity, antigen-antibody interaction, monoclonal antibodies, ovalbumin

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Qian, J., Y. Xing, D. Yufang, X. Deng, J. Zhao, Q. Wang, Z. Tian, M. LI und X. Zeng. „OP0216 THE CLINICAL AND PATHOLOGICAL ROLES OF AUTOANTIBODIES TARGETING BMP SIGNALING IN SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION“. Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 141.1–142. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3682.

Der volle Inhalt der Quelle

Annotation:

BackgroundPulmonary arterial hypertension (PAH) is one of the most severe complications and the leading cause of death in patients with systemic lupus erythematosus (SLE). Pathogenic mechanisms leading to SLE-PAH are still not fully understood. In idiopathic PAH, the dysfunction of the bone morphogenetic protein (BMP) pathway was found to be involved in pulmonary artery remodeling [1]. In SLE-PAH, our previous study identified serum autoantibodies targeting BMP receptors (BMPR) as the potential biomarker, including anti-BMPR2, BMPR1A, and Activin Receptor-Like Kinase type 1 (ALK1) antibodies [2]. However, the clinical and pathological roles of the above autoantibodies targeting BMP signaling in SLE-PAH remain uncertain.ObjectivesTo investigate the clinical and pathological roles of autoantibodies targeting BMPR2, BMPR1A, and ALK1 in SLE-PAH.MethodsPatients of SLE-PAH confirmed by right heart catheterization were enrolled and serum levels of autoantibodies targeting BMPR2, BMPR1A, and ALK1 were measured by ELISA. Patients with SLE-PAH were subtyped by cluster analysis. Survival and treatment goal achievement were further compared between different clusters. The Id1 and phospho-SMAD1/5 (p-SMAD1/5) levels were examined in human pulmonary artery endothelial cells (hPAEC) under the induction of BMP9 combined with anti-BMPR2, anti-ALK1, and anti-BMPR1A neutralizing antibodies (5 μg/mL). The effect of anti-ALK1 antibodies on the extent of monolayer permeability and apoptosis of hPAEC was further examined.Results60 SLE-PAH patients were enrolled and cluster analysis revealed two distinct clusters according to the positivity of autoantibodies targeting BMP signaling and clinical manifestations. Cluster 1 was a “low-antibody and high-disease activity” cluster while cluster 2 was a “high-antibody and low-disease activity” cluster. Patients in cluster 1 showed a higher proportion of nephropathy (76.9%) and SLE activity, however a low positivity rate of autoantibodies targeting BMP signaling. Patients in cluster 2 were characterized by a higher rate of anti-BMPR2 antibodies (82.4%), anti-ALK antibodies (70.6%), and lower SLE activity. Prognostic analysis showed that the proportion of patients who reached the treatment target was relatively higher in cluster 2. Mechanism study showed that the p-SMAD1/5 level and the Id1expression were decreased, indicating the suppression of BMP signaling in the presence of anti-ALK1 antibodies. Functional studies showed that anti-ALK1 antibodies increased the monolayer permeability of hPAEC. The late-stage apoptosis of hPAECs was also induced by anti-ALK1 antibodies.Table 1.The clinical features of the patients in cluster 1 and cluster 2.Cluster 1 (N=26)Cluster 2 (N=34)PAnti-BMPR2 antibodies5(19.2)28(82.4)<0.001Anti-BMPR1A antibodies8(30.2)4(1.8)0.068Anti-ALK antibodies5(19.2)24(70.6)<0.001Arthritis12(46.2)25(73.5)0.031Nephropathy20(76.9)1(2.9)<0.001SLEDAI5.46±4.282.62±2.100.001WHO III/IV17(65.4)14(41.2)0.063Figure 1.(A). Kaplan-Meier analysis of the prognosis of cluster1 and cluster2. (B) The level of Id1 expression under the induction of anti-BMPR2, anti-ALK1, and anti-BMPR1A antibodies in the presence or absence of BMP9. The ID1 (C) and p-Smad 1/5/8 (D) measured by western blotting under the induction of anti-ALK antibodies, BMP9, or anti-ALK antibodies+ BMP9. The fluorescence of the receiver plate well solution (E) and the percentage of late-stage apoptotic cells (E) under the induction of anti-ALK neutralizing antibodies.ConclusionThe serum positivity of autoantibodies targeting BMP signaling has clinical potential in dividing SLE-PAH patients into two distinct clusters. The anti-ALK1 antibodies can downregulate BMP signaling and mediate great permeability and apoptosis in hPAECs, which may be involved in the pathogenesis of SLE-PAH.References[1]Dewachter L, et.al. Eur Respir J 34 (5):1100-1110.[2]Xing Y, et.al. FASEB J 35 (12):e22044.AcknowledgementsWe thank CSTAR co-authors as following for assistance with cases collections.Disclosure of InterestsNone Declared.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Dahl, Mark V., und Alina G. Bridges. „Intravenous immune globulin: Fighting antibodies with antibodies“. Journal of the American Academy of Dermatology 45, Nr. 5 (November 2001): 775–83. http://dx.doi.org/10.1067/mjd.2001.119085.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

SHITARA, Kenya. „Potelligent Antibodies as Next Generation Therapeutic Antibodies“. YAKUGAKU ZASSHI 129, Nr. 1 (01.01.2009): 3–9. http://dx.doi.org/10.1248/yakushi.129.3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Methe, H. „Antibodies Stop Secretion of Antibodies in Lupus“. Science Translational Medicine 4, Nr. 141 (04.07.2012): 141ec115. http://dx.doi.org/10.1126/scitranslmed.3004529.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Filatova, Elena A., Grigory B. Krapivinsky, Grigory N. Filatov, Alisa V. Lazareva und Evgeny E. Fesenko. „Antiidiotypic antibodies against anti-cGMP polyclonal antibodies“. Biochimica et Biophysica Acta (BBA) - Biomembranes 1064, Nr. 2 (Mai 1991): 293–96. http://dx.doi.org/10.1016/0005-2736(91)90314-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Khan, Ramsha, Melissa Menard, Chao-Ching Jen, Xi Chen, Peter A. A. Norris und Alan H. Lazarus. „Inhibition of platelet phagocytosis as an in vitro predictor for therapeutic potential of RBC antibodies in murine ITP“. Blood 135, Nr. 26 (25.06.2020): 2420–24. http://dx.doi.org/10.1182/blood.2019003646.

Der volle Inhalt der Quelle

Annotation:

Abstract Polyclonal anti-D is a first-line therapy for immune thrombocytopenia (ITP). Monoclonal antibodies are desirable alternatives, but none have yet proven successful despite their ability to opsonize erythrocytes (or red blood cells, RBCs) and cause anemia. Here, we examined 12 murine erythrocyte–specific antibodies of different specificity and subtypes and found that 8 of these antibodies could induce anemia in antigen-positive mice. Of these 8 antibodies, only 5 ameliorated ITP. All antibodies were examined for their in vitro ability to support macrophage-mediated phagocytosis of erythrocytes. Antibodies which supported erythrocyte phagocytosis in vitro successfully ameliorated ITP in vivo. To examine the ability of each antibody to inhibit phagocytosis of platelets, the antibodies were used to sensitize erythrocytes in vitro and these were added to a platelet phagocytosis assay. Antibodies that inhibited platelet phagocytosis in vitro also all ameliorated ITP in vivo. We conclude that inducing anemia is not a sufficient condition for amelioration of ITP but that the antibody’s ability to prevent platelet phagocytosis in vitro predicted its ability to ameliorate ITP. We suggest that inhibition of in vitro platelet phagocytosis may prove to be a valuable tool for determining which erythrocyte antibodies would likely be candidates for clinical use in ITP.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Reddy, Raghuram, Joel Mintz, Roei Golan, Fakiha Firdaus, Roxana Ponce, Derek Van Booven, Aysswarya Manoharan, Isabelle Issa, Bonnie B. Blomberg und Himanshu Arora. „Antibody Diversity in Cancer: Translational Implications and Beyond“. Vaccines 10, Nr. 8 (22.07.2022): 1165. http://dx.doi.org/10.3390/vaccines10081165.

Der volle Inhalt der Quelle

Annotation:

Patients with cancer tend to develop antibodies to autologous proteins. This phenomenon has been observed across multiple cancer types, including bladder, lung, colon, prostate, and melanoma. These antibodies potentially arise due to induced inflammation or an increase in self-antigens. Studies focusing on antibody diversity are particularly attractive for their diagnostic value considering antibodies are present at an early diseased stage, serum samples are relatively easy to obtain, and the prevalence of antibodies is high even when the target antigen is minimally expressed. Conversely, the surveillance of serum proteins in cancer patients is relatively challenging because they often show variability in expression and are less abundant. Moreover, an antibody’s presence is also useful as it suggests the relative immunogenicity of a given antigen. For these reasons, profiling antibodies’ responses is actively considered to detect the spread of antigens following immunotherapy. The current review focuses on expanding the knowledge of antibodies and their diversity, and the impact of antibody diversity on cancer regression and progression.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Heng, Boon Chin, Wenjin Huang, Xiufang Zhong, Ping Yin und Guo Qing Tong. „Roles of Antiphospholipid Antibodies, Antithyroid Antibodies and Antisperm Antibodies in Female Reproductive Health“. Integrative Medicine International 2, Nr. 1-2 (16.07.2015): 21–31. http://dx.doi.org/10.1159/000381900.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

BYGREN, P., N. RASMUSSEN, B. ISAKSSON und J. WIESLANDER. „Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephritis“. European Journal of Clinical Investigation 22, Nr. 12 (Dezember 1992): 783–92. http://dx.doi.org/10.1111/j.1365-2362.1992.tb01447.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Kapustianenko, L. G. „POLYCLONAL ANTIBODIES AGAINST HUMAN PLASMINOGEN KRINGLE 5“. Biotechnologia Acta 10, Nr. 3 (Juni 2017): 41–49. http://dx.doi.org/10.15407/biotech10.03.041.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Triplett, Douglas A. „Antiphospholipid Antibodies“. Archives of Pathology & Laboratory Medicine 126, Nr. 11 (01.11.2002): 1424–29. http://dx.doi.org/10.5858/2002-126-1424-aa.

Der volle Inhalt der Quelle

Annotation:

Abstract Objective.—To review the role of lupus anticoagulants in the pathogenesis of both venous and arterial thromboembolic events, as well as in recurrent spontaneous abortions. The pathophysiology of lupus anticoagulants and associated antiphospholipid antibodies (eg, anticardiolipin antibodies) is also discussed. Data Sources.—Review of the recent medical literature. Data Extraction and Synthesis.—Key articles in the recent medical literature dealing with lupus anticoagulants and their role in pathogenesis of thromboembolic events were reviewed. Plasma proteins that have an affinity for binding to “perturbed cellular membranes” have been identified as the antigenic targets for antiphospholipid antibodies. Thus, the concept of antiphospholipid antibodies needs to be reevaluated. Perhaps a better term is antiprotein-phospholipid antibodies. The principal antigenic protein targets are β2-glycoprotein I, prothrombin, and a wide range of additional proteins that interact with activated cellular membranes, including protein C, protein S, annexin V, etc. Most research reported in the literature has focused on β2-glycoprotein I and human prothrombin.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Brinkmann, Ulrich, und Roland E. Kontermann. „Bispecific antibodies“. Science 372, Nr. 6545 (27.05.2021): 916–17. http://dx.doi.org/10.1126/science.abg1209.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Rieger, Paula Trahan. „Monoclonal Antibodies“. American Journal of Nursing 87, Nr. 4 (April 1987): 469. http://dx.doi.org/10.2307/3470440.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Groner, Bernd, Cord Hartmann und Winfried Wels. „Therapeutic Antibodies“. Current Molecular Medicine 4, Nr. 5 (01.08.2004): 539–47. http://dx.doi.org/10.2174/1566524043360483.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Kosmas, C., H. Kalofonos und A. A. Epenetos. „Monoclonal Antibodies“. Drugs 38, Nr. 5 (November 1989): 645–57. http://dx.doi.org/10.2165/00003495-198938050-00001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Larrick, James W., und Kirk E. Fry. „Recombinant antibodies“. Human Antibodies 2, Nr. 4 (01.12.1991): 172–89. http://dx.doi.org/10.3233/hab-1991-2401.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Bronson, Richard A. „Sperm Antibodies“. Immunology and Allergy Clinics of North America 10, Nr. 1 (Februar 1990): 165–84. http://dx.doi.org/10.1016/s0889-8561(22)00256-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Pisetsky, David S. „ANTINUCLEAR ANTIBODIES“. Immunology and Allergy Clinics of North America 14, Nr. 2 (Mai 1994): 371–85. http://dx.doi.org/10.1016/s0889-8561(22)00780-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Smith, J. Bruce, und F. Susan Cowchock. „ANTIPHOSPHOLIPID ANTIBODIES“. Immunology and Allergy Clinics of North America 14, Nr. 4 (November 1994): 821–34. http://dx.doi.org/10.1016/s0889-8561(22)00345-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Pratt, Donna E. „THYROID ANTIBODIES“. Immunology and Allergy Clinics of North America 14, Nr. 4 (November 1994): 835–38. http://dx.doi.org/10.1016/s0889-8561(22)00346-0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Visan, Ioana. „Enhancing antibodies“. Nature Immunology 22, Nr. 7 (28.06.2021): 800. http://dx.doi.org/10.1038/s41590-021-00973-7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Khamashta, Munther A., und Graham R. V. Hughes. „Antiphospholipid antibodies“. Clinical Reviews in Allergy 12, Nr. 3 (September 1994): 287–96. http://dx.doi.org/10.1007/bf02802323.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Adair, J., und A. Lawson. „Therapeutic Antibodies“. Drug Design Reviews - Online 2, Nr. 3 (01.05.2005): 209–17. http://dx.doi.org/10.2174/1567269053828800.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Pullen, Richard L. „Antinuclear antibodies“. Nursing Made Incredibly Easy! 20, Nr. 6 (November 2022): 47–48. http://dx.doi.org/10.1097/01.nme.0000884112.83689.31.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Santos-Argumedo, Leopoldo. „Natural Antibodies“. Advances in Neuroimmune Biology 3, Nr. 3,4 (2012): 345–52. http://dx.doi.org/10.3233/nib-012912.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

&NA;. „Monoclonal antibodies“. Reactions Weekly &NA;, Nr. 1293 (März 2010): 36. http://dx.doi.org/10.2165/00128415-201012930-00100.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Hudson, Peter J., und Christelle Souriau. „Engineered antibodies“. Nature Medicine 9, Nr. 1 (Januar 2003): 129–34. http://dx.doi.org/10.1038/nm0103-129.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Benkovic, Stephen J. „Catalytic Antibodies“. Annual Review of Biochemistry 61, Nr. 1 (Juni 1992): 29–54. http://dx.doi.org/10.1146/annurev.bi.61.070192.000333.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Harris, E. Nigel. „ANTIPHOSPHOLIPID ANTIBODIES“. British Journal of Haematology 74, Nr. 1 (07.07.2008): 1–9. http://dx.doi.org/10.1111/j.1365-2141.1988.00491.x-i1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Harris, E. Nigel. „ANTIPHOSPHOLIPID ANTIBODIES“. British Journal of Haematology 74, Nr. 1 (Januar 1990): 1–9. http://dx.doi.org/10.1111/j.1365-2141.1990.tb02530.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Drlicek, M., U. Liszka, W. Grisold, A. Mohn-Staudner, F. Lintner und K. Jellinger. „Antineuronal antibodies“. Neurology 40, Nr. 11 (01.11.1990): 1804. http://dx.doi.org/10.1212/wnl.40.11.1804-b.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Helmerhorst, F. M., M. J. J. Finken und J. J. Erwich. „Antisperm antibodies“. Human Reproduction 14, Nr. 7 (Juli 1999): 1669–71. http://dx.doi.org/10.1093/humrep/14.7.1669.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Worland, PhD, Peter J., Gary S. Gray, PhD, Mark Rolfe, PhD, Karen Gray, PhD und Jeffrey S. Ross, MD. „Anticancer Antibodies“. American Journal of Clinical Pathology 119, Nr. 4 (01.04.2003): 472–85. http://dx.doi.org/10.1309/y6lp-c0lr-726l-9dx9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Ross, Jeffrey S., Karen Gray, Gary S. Gray, Peter J. Worland und Mark Rolfe. „Anticancer Antibodies“. American Journal of Clinical Pathology 119, Nr. 4 (April 2003): 472–85. http://dx.doi.org/10.1309/y6lpc0lr726l9dx9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Barahona-Garrido, J., J. Camcho-Escobedo, C. Garcia-Martiʼnez, H. Tocay, J. Cabiedes und J. Yamamoto-Furusho. „Antinuclear antibodies“. Inflammatory Bowel Diseases 14 (Dezember 2008): S12. http://dx.doi.org/10.1097/00054725-200812001-00038.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Persidis, Aris. „Catalytic antibodies“. Nature Biotechnology 15, Nr. 12 (November 1997): 1313–15. http://dx.doi.org/10.1038/nbt1197-1313.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Tramontano, A., K. Janda und R. Lerner. „Catalytic antibodies“. Science 234, Nr. 4783 (19.12.1986): 1566–70. http://dx.doi.org/10.1126/science.3787261.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

&NA;. „Monoclonal Antibodies“. Journal of Pediatric Hematology/Oncology 25, Nr. 4 (April 2003): S5—S6. http://dx.doi.org/10.1097/00043426-200304000-00025.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

&NA;. „Monoclonal Antibodies“. Journal of Pediatric Hematology/Oncology 25, Nr. 4 (April 2003): S17—S18. http://dx.doi.org/10.1097/00043426-200304000-00036.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!